What Ani Pharmaceuticals Inc does.

ANI Pharmaceuticals is a diversified bio-pharmaceutical company. The Company's mission is “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands businesses.

On September 16, 2024, the Company acquired Alimera Sciences, Inc. ("Alimera"). In connection with the acquisition, the Company added two new products, ILUVIEN® ("ILUVIEN") and YUTIQ® ("YUTIQ"). See Note 3 "Business Combination" in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K.

During March 2025, the FDA approved an expanded label for ILUVIEN to include an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye ("NIU-PS") in addition to the then-current indication of Diabetic Macular Edema ("DME"). The Company is currently marketing ILUVIEN for both indications in the U.S. ILUVIEN was already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries. During the second quarter of 2025, the Company transitioned promotional efforts in the U.S. from YUTIQ to ILUVIEN with its combined label of DME and NIU-PS.

Revenue and profit, by fiscal year.

More on ANIP.

• Ani Pharmaceuticals Inc summary
• Ani Pharmaceuticals Inc financial statements
• Ani Pharmaceuticals Inc key metrics
• Ani Pharmaceuticals Inc health scores and style box
• Ani Pharmaceuticals Inc earnings
• Ani Pharmaceuticals Inc dividends
• Ani Pharmaceuticals Inc valuation
• Ani Pharmaceuticals Inc ownership and insiders
• Ani Pharmaceuticals Inc peers

Figures from Ani Pharmaceuticals Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.